<DOC>
	<DOC>NCT01449162</DOC>
	<brief_summary>The study objective is to compare the efficacy and the safety of masitinib at 6 mg/kg/day versus placebo in the treatment of patients with Severe Persistent Asthma treated with oral corticosteroids.</brief_summary>
	<brief_title>A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Placebo in Treatment of Patients With Severe Persistent Asthma Treated With Oral Corticosteroids</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>1. Patient with severe persistent asthma already treated 2. Patient with history of asthma &gt; 1 year prior to screening visit 3. Patient with no significant change in the regular asthma medication, no severe asthma exacerbation for at least 4 weeks prior to screening visit 4. Nonsmoker patient for at least one year and with a prior tobacco consumption &lt; 10 packs a year 1. Asthmatic patient still exposed to allergens or to triggering factors influencing asthma control 2. Patient with history of acute infectious sinusitis or respiratory tract infection within 4 weeks prior to screening 3. Patient presenting with cardiac disorders 4. Patient with active lung disease other than asthma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>severe persistent asthma</keyword>
	<keyword>patients treated with oral corticosteroids</keyword>
</DOC>